Literature DB >> 33430322

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia.

Marcus Bauer1, Christoforos Vaxevanis2, Haifa Kathrin Al-Ali3,4, Nadja Jaekel3, Christin Le Hoa Naumann3, Judith Schaffrath3, Achim Rau5, Barbara Seliger2,6, Claudia Wickenhauser1.   

Abstract

Background: Myelodysplastic syndromes (MDS) are caused by a stem cell failure and often include a dysfunction of the immune system. However, the relationship between spatial immune cell distribution within the bone marrow (BM), in relation to genetic features and the course of disease has not been analyzed in detail.
Methods: Histotopography of immune cell subpopulations and their spatial distribution to CD34+ hematopoietic cells was determined by multispectral imaging (MSI) in 147 BM biopsies (BMB) from patients with MDS, secondary acute myeloid leukemia (sAML), and controls.
Results: In MDS and sAML samples, a high inter-tumoral immune cell heterogeneity in spatial proximity to CD34+ blasts was found that was independent of genetic alterations, but correlated to blast counts. In controls, no CD8+ and FOXP3+ T cells and only single MUM1p+ B/plasma cells were detected in an area of ≤10 μm to CD34+ HSPC. Conclusions: CD8+ and FOXP3+ T cells are regularly seen in the 10 μm area around CD34+ blasts in MDS/sAML regardless of the course of the disease but lack in the surrounding of CD34+ HSPC in control samples. In addition, the frequencies of immune cell subsets in MDS and sAML BMB differ when compared to control BMB providing novel insights in immune deregulation.

Entities:  

Keywords:  CD34+ blasts; MDS; immune cell repertoire; multiplex immunohistochemistry; prognosis

Year:  2021        PMID: 33430322      PMCID: PMC7825771          DOI: 10.3390/cancers13020186

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  54 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.

Authors:  Wolf-K Hofmann; Sven de Vos; Martina Komor; Dieter Hoelzer; William Wachsman; H Phillip Koeffler
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

3.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors:  D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal:  Leukemia       Date:  2015-10-30       Impact factor: 11.528

4.  In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.

Authors:  Zhang Zheng; Zhang Qianqiao; He Qi; Xu Feng; Chang Chunkang; Li Xiao
Journal:  Exp Hematol       Date:  2010-04-13       Impact factor: 3.084

5.  Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design.

Authors:  Susann Winter; Saeed Shoaie; Shahram Kordasti; Uwe Platzbecker
Journal:  J Clin Oncol       Date:  2020-02-14       Impact factor: 44.544

6.  Identification of the haematopoietic stem cell niche and control of the niche size.

Authors:  Jiwang Zhang; Chao Niu; Ling Ye; Haiyang Huang; Xi He; Wei-Gang Tong; Jason Ross; Jeff Haug; Teri Johnson; Jian Q Feng; Stephen Harris; Leanne M Wiedemann; Yuji Mishina; Linheng Li
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

7.  TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Authors:  Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella
Journal:  Blood Adv       Date:  2020-10-27

8.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors:  Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

Review 9.  Galectins as regulators of cell survival in the leukemia niche.

Authors:  Peter P Ruvolo
Journal:  Adv Biol Regul       Date:  2018-09-12

10.  Risks of myeloid malignancies in patients with autoimmune conditions.

Authors:  L A Anderson; R M Pfeiffer; O Landgren; S Gadalla; S I Berndt; E A Engels
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  2 in total

Review 1.  Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities.

Authors:  Chiara Caprioli; Iman Nazari; Sara Milovanovic; Pier Giuseppe Pelicci
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 5.738

2.  Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers.

Authors:  Rachel M Koldej; Ashvind Prabahran; Chin Wee Tan; Ashley P Ng; Melissa J Davis; David S Ritchie
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.